A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Pumitamig
DRUG: Imzokitug
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb